Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 3
1992 1
1993 1
1994 1
1997 1
1999 1
2007 1
2008 1
2010 1
2012 2
2013 2
2015 1
2017 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Kruger S, Boeck S, Heinemann V, Laubender RP, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Modest DP, Stintzing S, Haas M. Kruger S, et al. Among authors: kojouharoff g. Acta Oncol. 2015 Jul;54(7):993-1000. doi: 10.3109/0284186X.2015.1034877. Epub 2015 Apr 30. Acta Oncol. 2015. PMID: 25924969 Clinical Trial.
Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE. Kropff M, et al. Among authors: kojouharoff g. Ann Hematol. 2017 Nov;96(11):1857-1866. doi: 10.1007/s00277-017-3065-z. Epub 2017 Sep 14. Ann Hematol. 2017. PMID: 28905189 Clinical Trial.
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S. Heinemann V, et al. Among authors: kojouharoff g. Gut. 2013 May;62(5):751-9. doi: 10.1136/gutjnl-2012-302759. Epub 2012 Jul 7. Gut. 2013. PMID: 22773551 Free PMC article. Clinical Trial.
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Boeck S, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler T, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Neugebauer S, Heinemann V. Boeck S, et al. Among authors: kojouharoff g. Anticancer Drugs. 2010 Jan;21(1):94-100. doi: 10.1097/CAD.0b013e32833123ed. Anticancer Drugs. 2010. PMID: 19770635 Clinical Trial.
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, Boeck HP, Schmid B, Kettner E, Stauch M, Lordick F, Ko Y, Geissler M, Schoppmeyer K, Kojouharoff G, Golf A, Neugebauer S, Heinemann V. Boeck S, et al. Among authors: kojouharoff g. Ann Oncol. 2008 Feb;19(2):340-7. doi: 10.1093/annonc/mdm467. Epub 2007 Oct 24. Ann Oncol. 2008. PMID: 17962204 Free article. Clinical Trial.
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Klein S, Kojouharoff G, Barner M, Geissler M, Greten TF, Mansmann U, Kirchner T, Heinemann V. Boeck S, et al. Among authors: kojouharoff g. Br J Cancer. 2013 Feb 5;108(2):469-76. doi: 10.1038/bjc.2012.495. Epub 2012 Nov 20. Br J Cancer. 2013. PMID: 23169292 Free PMC article. Clinical Trial.
15 results